Skip to main content
Bart PC Van de Warrenburg on Muck Rack

Bart PC Van de Warrenburg

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Bart PC

Contact Bart PC, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Slow-SPEED: protocol for three randomised trials of remotely delivered exercise to prevent Parkinson’s disease

|
By Thomas H. Oosterhof, Eleanor Mitchell, Alberto Ascherio, Stella Aslibekyan, Viktoria Azoidou, Kara Beasley, Yoav Ben-Shlomo, Eline M Bunnik, Camille B Carroll, Lana Chahine, Daniel Corcos, Jules M. Janssen Daalen, Karin van Dijk, Bauke W. Dijkstra, Lisanne J. Dommershuijsen, Ray Dorsey, Luc J. W. Evers, Rick C. Helmich, Martin Johansson, Lucy Norcliffe-Kaufmann, Jessi L. Keavney, Christine A. Klein, Matthew J Kmiecik, Thomas Kustermann, Eric Macklin, Kenneth Marek, Sanne K. Meles, Sebastiaan Overeem, Carl Philpott, Angelique Pijpers, Ronald B. Postuma, Helen Rowbotham, Sabine Schootemeijer, Michael A. Schwarzschild, Tanya Simuni, Michael Sommerauer, Ambra Stefani, Kenan Steidel, Marcel Verbeek, Nienke de Vries, Bart PC Van de Warrenburg, Richard K Wyse, Bastiaan R Bloem, Ruth Schneider, Alastair J. Noyce, Sirwan K. L. Darweesh, Rick van der Vliet
| Nature Verified
Abstract We describe the design of the first non-pharmacological Parkinson’s disease prevention trials worldwide: the randomised ‘Slow-SPEED’ trials. Three trials examine the feasibility and preliminary efficacy of a gamified, remotely administered exercise intervention vs. active control over 18–36 months in complementary prodromal subgroups: iRBD(n = 110; Netherlands), hyposmia(n = 110; United Kingdom) or LRRK2/GBA1 mutation carriers(n = 600; United States).
Open in Who Shared Issue with article?

Genetic variation in antidiabetic drug targets: associations with Parkinson’s disease risk and age at onset

|
By Katalin Vincze, Alexander Ploner, Robert Karlsson, Xiaoying Kang, Bowen Tang, Chenxi Qin, Cloé Domenighetti, Pierre-Emmanuel Sugier, Claudia Schulte, Patrick May, Dheeraj Reddy Bobbili, Milena Radivojkov-Blagojevic, Peter Lichtner, Andrew Singleton, Dena Hernandez, Connor Edsall, George D. Mellick, Alexander Zimprich, Walter Pirker, Ekaterina Rogaeva, Anthony E Lang, Sulev Kõks, Pille Taba, Suzanne Lesage, Alexis Brice, Jean-Christophe Corvol, Marie-Christine Chartier-Harlin, Eugénie Mutez, Kathrin Brockmann, Angela B. Deutschländer, Lena F. Burbulla, Georges M. Hadjigeorgiou, Efthimos Dardiotis, Leonidas Stefanis, Athina Maria Simitsi, Enza Maria Valente, Simona Petrucci, Letizia Straniero, Anna Zecchinelli, Gianni Pezzoli, Laura Brighina, Carlo Ferrarese, Grazia Annesi, Andrea Quattrone, Monica Gagliardi, Hirotaka Matsuo, Akiyoshi Nakayama, Nobutaka Hattori, Kenya Nishioka, Sun Ju Chung, Yun Joong Kim, Pierre Kolber, Bastiaan R Bloem, Mathias Toft, Lasse Pihlstrøm, Leonor Correia Guedes, Joaquim J Ferreira, Soraya Bardien, Jonathan Carr, Eduardo Tolosa, Mario Ezquerra, Caroline Ran, Andrea C. Belin, Andreas Puschmann, Carl Clarke, Karen Morrison Verified, Manuela MX Tan, Dimitri Krainc, Matt J. Farrer, Zied Landoulsi, Rejko Kruger, Thomas Gasser, Alexis Elbaz, Manu Sharma, Nancy L Pedersen, Sofia Carlsson, Sara Hägg, Karin Wirdefeldt, Agnieszka Szwajda, Bart PC Van de Warrenburg
| Nature Verified
Abstract To investigate whether antidiabetic drugs have a biological basis to be repurposed in PD prevention, we applied a drug target Mendelian randomization framework to assess associations between genetic variation in antidiabetic drug targets and PD risk or age at onset (AAO).
Open in Who Shared Issue with article?
See all 2 articles